Traders Buy Large Volume of Call Options on Hologic (HOLX)

Hologic (NASDAQ:HOLX) saw some unusual options trading activity on Wednesday. Investors purchased 2,770 call options on the stock. This represents an increase of 2,373% compared to the typical volume of 112 call options.

In other Hologic news, Director Charles J. Dockendorff bought 13,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was bought at an average cost of $38.80 per share, for a total transaction of $504,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Namal Nawana bought 6,600 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the transaction, the director now directly owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The disclosure for this purchase can be found here. Insiders own 0.79% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Hologic in the fourth quarter worth $235,000. Xact Kapitalforvaltning AB lifted its holdings in shares of Hologic by 4.3% in the fourth quarter. Xact Kapitalforvaltning AB now owns 67,102 shares of the medical equipment provider’s stock worth $2,869,000 after buying an additional 2,787 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Hologic by 4.6% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 150,391 shares of the medical equipment provider’s stock worth $6,429,000 after buying an additional 6,590 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Hologic by 12.5% in the fourth quarter. William Blair Investment Management LLC now owns 17,968 shares of the medical equipment provider’s stock worth $768,000 after buying an additional 1,999 shares in the last quarter. Finally, OLD Mutual Customised Solutions Proprietary Ltd. lifted its holdings in shares of Hologic by 49.1% in the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 16,400 shares of the medical equipment provider’s stock worth $701,000 after buying an additional 5,400 shares in the last quarter. 97.51% of the stock is currently owned by hedge funds and other institutional investors.

HOLX stock opened at $39.16 on Thursday. Hologic has a one year low of $35.33 and a one year high of $46.80. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The firm has a market capitalization of $10,693.38, a PE ratio of 18.86, a P/E/G ratio of 1.74 and a beta of 0.85.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. equities research analysts predict that Hologic will post 2.25 EPS for the current year.

Several brokerages recently issued reports on HOLX. BidaskClub upgraded shares of Hologic from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Goldman Sachs set a $43.00 price target on shares of Hologic and gave the stock a “buy” rating in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Friday, February 9th. Deutsche Bank lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Friday, January 19th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company’s stock. Hologic presently has an average rating of “Buy” and an average target price of $47.21.

ILLEGAL ACTIVITY NOTICE: “Traders Buy Large Volume of Call Options on Hologic (HOLX)” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/04/19/traders-buy-large-volume-of-call-options-on-hologic-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply